OQROStart free trial
Insider trade

Johnson & Johnson (JNJ): CFO sold ~$2M

Joseph J Wolk, CFO at Johnson & Johnson, sold ~$2M of Johnson & Johnson shares.

~$2M
Approx. value · 13K sh @ $153.89
Traded
Feb 7, 2025
Filed
Feb 12, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Nov 8, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  2. Dec 6, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  3. Dec 10, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  4. Dec 12, 2024InsiderDirector purchased ~$147K of JNJ shares in the open market
  5. Dec 12, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  6. Dec 24, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  7. Dec 31, 2024CongressDisclosed sale of JNJ — reported range $100,001 - $250,000
  8. Jan 8, 2025Congress · 1 personMembers of Congress: 4 purchases
  9. Jan 16, 2025CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  10. Jan 21, 2025CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  11. Jan 24, 2025Congress · 2 peopleMembers of Congress: 1 purchase, 1 sale
  12. Feb 7, 2025 · this disclosureInsiderCFO sold ~$2M of JNJ shares in the open market

What came next

  1. Feb 18, 2025InsiderChair sold ~$63K of JNJ shares in the open market
  2. Feb 24, 2025CongressDisclosed purchase of JNJ — reported range $15,001 - $50,000
  3. Feb 25, 2025InsiderOfficer sold ~$1.16M of JNJ shares in the open market
  4. Feb 28, 2025FDAFDA drug approval: Opsumit
  5. Mar 3, 2025CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  6. Mar 4, 2025CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  7. Mar 5, 2025CongressDisclosed purchase of JNJ — reported range $15,001 - $50,000
  8. Mar 7, 2025FDARecall: PDS¿PLUS¿VIO¿30IN(75CM)¿USP6-0(M0.7)¿D/A¿C-1¿MP
  9. Mar 7, 2025FDARecall: PROLENE BLU 18IN(45CM) USP6-0(M0.7) S/A P-1 PRM
  10. Mar 7, 2025FDARecall: ETHIBOND EXCEL GRN 36IN(90CM) USP2-0(M3) D/A MH
  11. Mar 7, 2025FDARecall: PDSII¿VIO¿30IN(75CM)¿USP6-0(M0.7)¿D/A¿C-1
  12. Mar 7, 2025CongressDisclosed partial sale of JNJ — reported range $1,001 - $15,000
  13. Mar 20, 2025FDAFDA drug approval: Tremfya
  14. Mar 21, 2025FDAFDA drug approval: Prezcobix
  15. Mar 24, 2025CongressDisclosed sale of JNJ — reported range $100,001 - $250,000
  16. Mar 28, 2025FDAFDA device clearance: Synthes Graphic Case & Tray System
  17. Mar 31, 2025CongressDisclosed purchase of JNJ — reported range $15,001 - $50,000
  18. Apr 1, 2025CongressDisclosed sale of JNJ — reported range $1,001 - $15,000
  19. Apr 8, 2025CongressDisclosed sale of JNJ — reported range $1,001 - $15,000
  20. Apr 9, 2025CongressDisclosed partial sale of JNJ — reported range $1,001 - $15,000
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Johnson & Johnson

For Johnson & Johnson, OQRO holds 14 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports, 119 fund holdings reports (13F) and 6 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its JNJ page.

Other recent filings by Joseph J Wolk, Exec VP, CFO

The full history of Joseph J Wolk, Exec VP, CFO is on the profile page.

How this filing works

Explore the data

Other disclosures at Johnson & Johnson

Everything OQRO holds on this company is on its JNJ page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Start free trialAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data